|
Gametocyte prevalence on days 0, 7, 14, 21 and 28 after treatment in patients with adequate parasitological response |
|||||
| Gametocyte prevalence, %, (n/N) |
|||||
|
|
|||||
| After treatment |
|||||
|
|
|||||
| At enrolment |
Day 7 |
Day 14 |
Day 21 |
Day 28 |
|
|
|
|||||
| CQ |
4.7 (2/42) |
12.5 (3/24)* |
4.2 (1/24)* |
6.6 (1/15) |
0 (0/15) |
| AQ |
12.8 (5/39) |
13.1 (5/38)* |
10.5 (4/38)* |
9.6 (3/31) |
0 (0/30) |
| SP |
10.2 (4/39) |
44.4 (16/36) |
33.3 (12/36) |
17.1 (6/35) |
6.1 (2/33) |
| AQ+SP |
2.4 (2/83) |
3.8 (3/80)* |
6.3 (5/80)* |
1.3 (1/75)¶ |
1.3 (1/75) |
| AQ+AS |
3.6 (3/83) |
2.5 (2/80)* |
1.2 (1/79)* |
1.5 (1/64)¶ |
0 (0/64) |
|
CQ, Chloroquine, AQ, amodiaquine; SP, Sulphadoxine-Pyrimethamine; AS, artesunate; 95% CI, 95% confidence interval. * On day 7 and day 14, significant difference to SP group (P < 0.05) ¶On day 21, significant difference to SP group (P < 0.05) | |||||
Ménard et al. Malaria Journal 2007 6:65 doi:10.1186/1475-2875-6-65 |
|||||